Document is current

Article History

Received: 30 January 2023

Accepted: 5 April 2023

First Online: 21 April 2023

Declarations

:

: This article contains results derived from data from human participants collected by several studies performed by previous studies. All participants gave informed consent in all the corresponding original studies. Our study is based on the large-scale GWAS datasets, and not the individual-level data. Hence, ethical approval was not applicable.

: Not applicable.

: JARQ was on the speakers bureau and/or acted as consultant for Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogi, Sincrolab, Novartis, BMS, Medice, Technofarma, Rubió and Raffo in the last 3 years. He also received travel awards (air tickets + hotel) for taking part in psychiatric meetings from Janssen-Cilag, Rubió, Shire, Takeda, Shionogi, Bial and Medice. The Department of Mental Health chaired by him received unrestricted educational and research support from the following companies in the last 3 years: Janssen-Cilag, Shire, Oryzon, Roche, Psious, and Rubió. ARU was on the speakers bureau and/or acted as consultant for Janssen-Cilag and Organon in tha last two years. All other authors declare no biomedical financial interests or conflicts of interest. JS has served as consultant for Noventure SL, Devintecpharma, Aboca, Reckitt, Ipsen and Pileje and discloses present and past recent scientific collaborations with Salvat, Norgine, Alfa-Sigma, Cosmo, Adare, Ordesa and Danone that do not constitute a conflict of interest in developing the content of the present manuscript. MS was on the speakers bureau and/or acted as consultant/advisory Board member for Tillotts, Menarini, Kyowa Kirin, Takeda, Biocodex, AlfaSigma, Sanofi, Janssen Immunology, Pfizer, Ferrer, BioGaia, Falk Foundation, Danone Nutricia Research, Ironwood, Genetic Analysis AS, DSM, Arena, Adnovate and Pharmanovia. He also was funded by Glycom/DSM research Grants.